However, in pancreatic cancer, oncogenic KRAS activates the ERK pathway, which, in turn, phosphorylates KLF11, and abrogates KLF11/SIN3a interaction, leading to transcriptional activation of SMAD7 and tumor progression. The gene discussed is KLF11; the disease is neoplasm.